Idorsia Ltd., a leading Swiss biopharmaceutical company, and Syneos Health® announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.
Syneos Health was initially selected as Idorsia’s commercial sales force partner in August 2020 to effectively reach the US primary care market. To support the potential launch in Europe and Canada, Idorsia is accessing a robust customer-facing field sales expertise, and operational and launch experience across Europe and Canada to help bring daridorexant to patients suffering from insomnia and in need of a new and innovative therapeutic solution.
Idorsia recently announced that it received U.S. FDA approval of QUVIVIQ 25 mg and 50 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (daridorexant) 25 and 50 mg for the treatment of adults with insomnia.
Idorsia plans to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia.
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. In order to achieve this, the company will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Syneos Health® brings together approximately 28,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together they share insights, use the latest technologies and apply advanced business practices to speed its customers’ delivery of important therapies to patients.
Takeaway: Idorsia’s collaboration with Syneos Health plans to effectively reach the primary care market in Europe and Canada